Michael Jain, MD, PhD
Moffitt Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Jain, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06553872 · Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLH. Lee Moffitt Cancer Center and Research Institute · recruiting · Mantle Cell Lymphoma · principal investigator
- Ph2NCT06104592 · Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLH. Lee Moffitt Cancer Center and Research Institute · recruiting · Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT05757219 · Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyH. Lee Moffitt Cancer Center and Research Institute · recruiting · Diffuse Large B Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.